Bolt Biotherapeutics (BOLT) Net Margin (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Net Margin of 33261.54% for Q1 2026, down 9605.16% sequentially from 342.72% in Q4 2025, and down 3225466.0% YoY from N/an in Q1 2025.
Bolt Biotherapeutics (BOLT) Net Margin (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Net Margin for 7 years, with the latest figure at 33261.54% in Q1 2026.
- Quarterly Net Margin fell 3225466.0% year-over-year to 33261.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1539.42% (up 41074.0% YoY) and the FY2025 annual result came in at 1783.11%, up 42571.0% from the prior year.
- Net Margin fell to 33261.54% in Q1 2026 per BOLT's latest filing, from 342.72% in the prior quarter.
- Over five years, Net Margin peaked at 316.4% in Q1 2024 and troughed at 33261.54% in Q1 2026.
- A 5-year average of 3938.41% and a median of 1890.45% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2026: Net Margin soared 563372 bps in 2022, then slumped 3225466 bps in 2026.
- Over 5 years, Net Margin stood at 1523.53% in 2022, then jumped by 63 bps to 566.78% in 2023, then sank by 157 bps to 1457.84% in 2024, then surged by 76 bps to 342.72% in 2025, then sank by 9605 bps to 33261.54% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 33261.54%, 342.72%, and 1847.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Bolt Biotherapeutics | 5.48 Mn | 5.48 Mn | - | -163,920.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -741,100.00% |
| Mar 31, 2026 | -33,261.54% |
| Dec 31, 2025 | -342.72% |
| Sep 30, 2025 | -1,847.40% |
| Jun 30, 2025 | -2,370.34% |
| Mar 31, 2025 | -1,006.87% |
| Sep 30, 2024 | -1,457.84% |
| Jun 30, 2024 | -1,682.67% |
| Mar 31, 2024 | -316.40% |
| Dec 31, 2023 | -566.78% |
| Sep 30, 2023 | -1,933.50% |
| Jun 30, 2023 | -3,612.63% |
| Mar 31, 2023 | -2,743.37% |
| Dec 31, 2022 | -1,523.53% |
| Sep 30, 2022 | -2,735.56% |
| Jun 30, 2022 | -4,181.05% |
| Mar 31, 2022 | -3,432.35% |
| Dec 31, 2021 | -5,706.10% |
| Sep 30, 2021 | -8,369.28% |
| Jun 30, 2020 | -19,167.16% |